多巴丝肼联合普拉克索治疗帕金森的临床疗效及安全性分析

Clinical Efficacy and Safety of Benserazide Combined with Pramipexole in the Treatment of Parkinson

目的探析多巴丝肼联合普拉克索治疗帕金森的临床疗效及安全性,旨在为今后临床用药提供参考依据。方法前瞻性选择我院2015年5月—2016年5月期间收治的60例帕金森病患者为研究对象,采用随机数字表法分为2组,每组各30例;对照组给予多巴丝肼治疗,治疗组给予多巴丝肼联合普拉克索治疗;观察两组患者临床疗效及UPDRS评分。结果治疗组总有效率为93.34%,明显高于对照组的73.33%(P<0.05);经治疗后,两组患者UPDRS评分较治疗前明显降低(P<0.05),且治疗组UPDRS评分较对照组降低程度更低(P<0.05);治疗组不良反应率为13.33%,明显低于对照组的40.00%(P<0.05)。结论多巴丝肼联合普拉克索治疗帕金森的临床疗效显著,安全性高,值得临床应用与推广。

Objective To analyze the clinical efficacy and safety of Benserazide combined with pramipexole in treatment of Parkinson and provide reference for future clinical use. Methods 60 Parkinsons patients treated in our hospital from May 2015 to May 2016 were prospectively selected as objects and divided into 2 groups, 30 cases each group according to random number table. The control group was given Benserazide treatment and the treatment group was treated with Benserazide combined with pramipexole. The clinical efficacy of the two groups was observed and UPDRS scores were recorded. Results The overall response rate of the treatment group was 93. 34% , significantly higher than 73. 33% of the control group （P 〈 0. 05 ） . UPDRS scores of both groups were significantly lower after the treatments （P 〈 0. 05 ） , of which UPDRS scores of the treatment group was lower than the control group （P 〈 0. 05 ） . The adverse reactions rate of the treatment group was 13. 33% , significantly lower than that of the control group, which was 40. 00% （P 〈 0. 05 ） . Conclusion Benserazide combined with pramipexole has a significant clinical effect on the treatment of Parkinson disease. It is also safe and worthy of clin-ical application and promotion.